IP PORTFOLIO – FAMILY 1
This group is based on an international patent application (PCT/US2009/038351)
- Focuses on the composition of matter of new synthetic versions of a peptide that stimulates the release of human growth hormone (hGHRH), including MIA-602 (our Treatment)
- Six patents have been issued: two in the US, and one each in Canada, China, Europe, and Japan.
- Unless extended, patents in this family expire in 2029.
IP PORTFOLIO – FAMILY 2
This group is based on an international patent application (PCT/US2020/017375)
- Focuses on creating and studying new synthetic versions of human growth hormone (hGHRH), including AVR-352, specifically for treating lung diseases.
- As of September 23, 2024, one patent has been granted in the US, and another US patent application is still pending. Unless extended, these patents will expire in 2040.
- The granted US patent covers methods for reducing lung inflammation, minimizing lung scarring, and improving symptoms of pulmonary fibrosis (PF).
IP PORTFOLIO – FAMILY 3
This patent group is based on an international patent application (PCT/US2020/042540)
- Focuses on materials and methods for treating sarcoidosis using synthetic versions of human growth hormone (hGHRH) such as MIA-602 (our treatment).
- As of September 23, 2024, three patents have been granted: one each in China, Europe, and Hong Kong.
- There are also five pending patent applications: one each in the US, China, Canada, Japan, and Europe.
- Unless extended, these patents will expire in 2040.
IP PORTFOLIO – FAMILY 4
This patent group is based on an international patent application (PCT/US2021/029218)
- Focuses on a method to treat inflammatory disorders, such as sarcoidosis, using a synthetic version of hGHRH, such as MIA-602 (our treatment).
- As of September 23, 2024, there is one pending application in the US and one in Canada.
- Unless extended, patents in this group will expire in 2041.